Belfast, UK – Artelo Biosciences has reached a significant milestone in the development of its innovative therapeutic candidate, ART27.13, by successfully dosing the first patient in the Phase II DREAM study. This pivotal trial is designed to rigorously investigate the potential of ART27.13, an orally administered synthetic cannabinoid, to manage intraocular pressure (IOP) in individuals suffering from glaucoma or ocular hypertension. The study’s design hinges on understanding how ART27.13 interacts with cannabinoid receptors within eye tissue, offering a promising new avenue for conditions that can lead to irreversible vision loss.
The DREAM study, a testament to collaborative research and development, is being sponsored by the Belfast Health and Social Care Trust, with the operational expertise of the Northern Ireland Clinical Trials Unit. Crucial financial backing for this endeavor has been provided by Glaucoma UK and the Health and Social Care research and development (HSC R&D) division, underscoring the widespread recognition of the urgent need for more effective glaucoma treatments. Leading the scientific charge is Professor Augusto Azuara-Blanco, a distinguished ophthalmology clinical professor at Queen’s University Belfast and an honorary consultant ophthalmologist at the Belfast Health and Social Care Trust. His leadership promises to guide the study with the highest scientific integrity and clinical acumen.
ART27.13 represents a novel approach in the therapeutic landscape. It is classified as a peripherally selective synthetic cannabinoid receptor agonist. This specific characteristic is of paramount importance, as it suggests a potential to target the desired therapeutic effects in the eye while minimizing unwanted central nervous system (CNS) side effects that have historically plagued the development of other cannabinoid-based therapies.
Gregory Gorgas, President and CEO of Artelo Biosciences, expressed considerable enthusiasm regarding this development. "We are thrilled to announce that the first patient has been enrolled in this fully funded Phase II clinical study, evaluating ART27.13 for glaucoma," Gorgas stated. "The DREAM study holds the potential to definitively demonstrate whether an orally active cannabinoid can play a significant role in managing intraocular pressure. ART27.13’s peripherally selective design is a key differentiator, and we believe it may successfully circumvent the CNS adverse effects that have presented challenges with other oral or topical cannabinoids explored for this indication. We eagerly anticipate releasing the initial results from the DREAM study later this year."
Understanding the Mechanism: Cannabinoid Receptors and Intraocular Pressure
Glaucoma and ocular hypertension are serious eye conditions characterized by elevated intraocular pressure, which can damage the optic nerve and lead to progressive vision loss. Current treatments, while effective for many, can have limitations and side effects, prompting a continuous search for novel therapeutic agents. The endocannabinoid system, a complex cell-signaling network involved in regulating various physiological processes, has emerged as a potential target for IOP reduction.
Cannabinoid receptors, primarily CB1 and CB2, are found throughout the body, including in ocular tissues such as the ciliary body, iris, retina, and trabecular meshwork. These receptors are activated by endocannabinoids produced naturally by the body and by exogenous cannabinoids, like those found in cannabis or synthetic compounds. Research suggests that modulating the activity of these receptors can influence the production and outflow of aqueous humor, the fluid within the eye, thereby affecting IOP.
ART27.13’s specific action as a dual cannabinoid agonist means it can interact with both CB1 and CB2 receptors. Its peripherally selective nature is designed to enhance its activity at these receptors in the eye while limiting its passage across the blood-brain barrier, thus reducing the likelihood of psychoactive or other CNS-related side effects. This targeted approach is a significant advancement, potentially offering a more tolerable and effective treatment option for patients.
Chronology of Development: A Journey Towards Novel Therapies
The development of ART27.13 is built upon a foundation of prior research and clinical evaluation. Originally developed by AstraZeneca, ART27.13 is a benzimidazole derivative that has undergone extensive preclinical and clinical investigation.
- Preclinical Research: Extensive laboratory studies have explored the pharmacological properties of ART27.13, focusing on its binding affinity to cannabinoid receptors and its effects on IOP in animal models. These studies have provided the rationale for its progression into human clinical trials.
- Previous Clinical Studies: ART27.13 has been evaluated in seven previous clinical studies, involving a combined total of over 280 participants. These studies have provided crucial safety and preliminary efficacy data, informing the design of the current Phase II DREAM study. These earlier investigations have helped to establish a foundational understanding of the compound’s tolerability and its potential impact on various physiological parameters.
- Phase II DREAM Study Initiation: The dosing of the first patient in the Phase II DREAM study marks a critical juncture, moving ART27.13 into a phase of more targeted efficacy evaluation for specific ophthalmic conditions. This study is specifically designed to provide robust data on ART27.13’s ability to lower IOP.
- Recent Regulatory Milestones: In a separate but related development, in July 2024, the U.S. Food and Drug Administration (FDA) approved Artelo Biosciences’ investigational new drug (IND) application for its fatty acid binding protein (FABP) inhibitor. This cleared the way for a Phase I trial for that compound, demonstrating Artelo’s broader commitment to developing innovative therapies across different mechanisms of action. While distinct from ART27.13, this regulatory success highlights the company’s growing pipeline and its ability to navigate the complex drug development landscape.
Supporting Data and Scientific Rationale
The scientific premise behind ART27.13’s potential efficacy in glaucoma and ocular hypertension is rooted in the established roles of the endocannabinoid system in ocular physiology. Studies have indicated that activation of cannabinoid receptors, particularly CB1 receptors in the trabecular meshwork and ciliary body, can lead to a decrease in aqueous humor outflow resistance and/or a reduction in aqueous humor production, both of which contribute to lower IOP.
Furthermore, the anti-inflammatory properties associated with cannabinoid receptor activation may also play a beneficial role in managing glaucoma, a condition that is increasingly understood to have inflammatory components. The neuroprotective potential of cannabinoids is also an area of active research, which could offer additional benefits to the optic nerve.
The "peripherally selective" aspect of ART27.13 is a critical differentiator. Previous attempts to leverage cannabinoids for IOP management have been hampered by the significant CNS side effects associated with non-selective compounds. These can include dizziness, fatigue, and cognitive impairment, which can limit patient compliance and overall treatment success. By targeting cannabinoid receptors predominantly in the periphery, ART27.13 aims to achieve therapeutic benefits in the eye without these debilitating systemic effects.
The DREAM study’s design will meticulously measure changes in IOP over time in participants treated with ART27.13 compared to a placebo. Additionally, researchers will monitor for any adverse events, both ocular and systemic, to thoroughly assess the safety profile of the compound. Biomarkers related to aqueous humor dynamics and optic nerve health may also be investigated to provide further insight into the drug’s mechanism of action and its potential to preserve vision.
Official Responses and Stakeholder Engagement
The initiation of the DREAM study has been met with considerable optimism from key stakeholders involved in glaucoma research and patient advocacy.
Artelo Biosciences: As mentioned, CEO Gregory Gorgas has articulated a clear vision for ART27.13, emphasizing its potential to overcome the limitations of existing therapies. The company’s strategic focus on peripherally selective cannabinoids is a key differentiator, and the successful enrollment of the first patient is a significant step in validating this approach. Artelo’s commitment to transparency and timely dissemination of results underscores their dedication to advancing the field.
Belfast Health and Social Care Trust and Northern Ireland Clinical Trials Unit: As the sponsor and operational lead, respectively, their involvement signifies a strong commitment to advancing cutting-edge medical research within Northern Ireland. The trust’s role in facilitating clinical trials underscores its dedication to improving patient care through innovation. The clinical trials unit’s expertise ensures that the study is conducted to the highest international standards.
Glaucoma UK and HSC R&D Division: The funding provided by these organizations highlights the critical need for novel treatments for glaucoma and ocular hypertension. Glaucoma UK, a leading charity dedicated to fighting sight loss, actively supports research that can lead to better management and prevention of glaucoma. The HSC R&D division’s investment demonstrates a commitment to fostering a vibrant research ecosystem that translates into tangible benefits for patients.
Professor Augusto Azuara-Blanco: As the lead investigator, his expertise in ophthalmology and clinical trial design is invaluable. His leadership ensures that the study is scientifically rigorous and clinically relevant, prioritizing patient safety and the generation of meaningful data. His involvement adds significant credibility to the DREAM study.
Implications for the Future of Glaucoma Treatment
The successful development and potential approval of ART27.13 could have profound implications for the management of glaucoma and ocular hypertension.
- A New Oral Therapeutic Option: The availability of an orally administered treatment for these conditions would be a significant advancement. Many patients find topical eye drops inconvenient or difficult to administer consistently. An oral medication could improve adherence and simplify treatment regimens.
- Reduced Side Effect Profile: If ART27.13 proves to be well-tolerated with minimal CNS side effects, it could offer a safer alternative for patients who experience adverse reactions to existing treatments or who are seeking options with fewer systemic impacts.
- Broader Applicability: The potential to manage IOP through cannabinoid receptor modulation opens up new avenues for research into other ophthalmic conditions where elevated IOP is a contributing factor.
- Advancement in Cannabinoid Therapeutics: The success of ART27.13 could pave the way for further development of peripherally selective cannabinoid agonists for a range of medical indications, demonstrating the therapeutic potential of targeted cannabinoid therapies beyond their well-known applications.
The coming months will be crucial as the DREAM study progresses and generates initial data. The ophthalmic community, patients, and researchers will be keenly watching for the results, hopeful that ART27.13 will represent a significant leap forward in the fight against vision loss caused by glaucoma and ocular hypertension. This Phase II trial is not just about evaluating a single drug; it is about exploring a new paradigm in ophthalmic therapeutics, driven by a deeper understanding of the body’s own signaling systems and the innovative application of synthetic compounds.
About the Author
